3.4 Stimulants: Intoxication, Crash, and Crisis Risk

Stimulants: activation, not sedation

Stimulants include cocaine, methamphetamine, prescription amphetamines (Adderall, dextroamphetamine) and methylphenidate used outside directions, and related drugs. They flood the brain with dopamine, norepinephrine, and serotonin, so the exam theme is activation: increased energy, pressured speech, reduced sleep, restlessness, irritability, dilated (mydriatic) pupils, sweating, suspiciousness, and inflated confidence. This is the mirror image of the depressant picture — a useful contrast the exam tests directly.

Cocaine is short-acting (the high may last under an hour, prompting repeated dosing in a binge); methamphetamine is long-acting (a single use can last many hours), driving days-long sleeplessness sometimes called a "run." At higher risk levels, stimulant use links to panic, paranoia, aggression, risky sex, dehydration, overheating, chest pain, and stimulant-induced psychosis with hallucinations or delusions (classically, the sensation of bugs under the skin — formication, leading to skin-picking sores). Methamphetamine also produces characteristic dental decay ("meth mouth") and weight loss with chronic use.

A crucial pharmacology contrast: cocaine blocks reuptake of dopamine, while amphetamines also force release of dopamine, which is part of why methamphetamine effects are longer and the neurotoxicity concern is greater. The counselor does not need this to prescribe — it explains why the crash, craving, and cognitive effects can be prolonged after methamphetamine.

Stimulant overdose is a different emergency

Unlike opioids, stimulants have no specific reversal agent — overdose care is supportive and medical. The exam wants you to recognize the cardiovascular and neurologic red flags and refer urgently:

Hyperthermia is a leading contributor to morbidity and mortality in cocaine, amphetamine, and other psychostimulant poisoning and is a hallmark of toxic states. The CADC does not diagnose a cardiac or neurologic event — but recognizes that chest pain, seizure, severe headache, or dangerously high temperature shifts the task from persuasion to urgent medical referral or emergency response.

Applied scenario: a client in group is pacing, has not slept in three days, says people are watching the building, and is sweating heavily. The best answer is not to debate the belief or push insight. A CADC maintains safety, reduces stimulation, consults, and follows crisis or medical referral policy. Paranoia is handled with calm safety steps, never argument. Sweating plus agitation should also prompt concern for hyperthermia, which is the silent killer in stimulant toxicity — a reason this is a medical-referral scenario, not just a behavioral one.

Note that prescription stimulants (used for ADHD) are commonly diverted and misused for studying, weight loss, or performance, so the exam can present a college student or shift worker rather than a stereotyped "street" user. The same activation, crash, and crisis logic applies; legality of the original prescription does not lower the risk.

The crash, craving, and crisis triage

The stimulant crash follows a binge or heavy-use period. The client may sleep for long stretches, feel exhausted and ravenous, become depressed, and experience powerful craving. This is a vulnerable window for return to use and for self-harm — the depressive crash can include hopelessness and suicidal ideation. Stimulant withdrawal/crash is rarely medically dangerous in the depressant sense (no characteristic seizures or DTs), but it is psychologically dangerous, so suicide-risk screening is essential.

Applied scenario: a client reports stopping methamphetamine and now feels empty, ashamed, and unable to get out of bed. The CADC should assess depression and suicide risk, support engagement, and connect the client to mental-health or medical care when indicated. It is still a substance-use counseling context, but the safety screen leads.

Common exam traps:

• Treating every stimulant presentation as a motivation problem. Agitation, paranoia, chest pain, or threats shift the task to safety; MI helps after stabilization, not before.
• Assuming all withdrawals are equally life-threatening. Alcohol and sedative withdrawal carry seizure/delirium risk; the stimulant crash emphasizes mood, craving, exhaustion, and suicide assessment instead.
• Labeling psychosis-like beliefs as "crazy" or "manipulative." Document behavior, not judgments.

Documentation should be behavioral and specific: slept two hours in three days, paced in hallway, stated people outside were following him, endorsed/denied suicidal thoughts, supervisor contacted, referral made. Avoid unsupported labels. There is no FDA-approved medication specifically for stimulant use disorder comparable to opioid MOUD, so the evidence base centers on contingency management and psychosocial treatment — a point the exam may use to test that medication is not the answer for every class.

• Stimulants activate the CNS; overdose is cardiac, neurologic, and hyperthermic.
• No naloxone-equivalent exists; chest pain or seizure means urgent referral.
• The crash brings depression and craving — always screen suicide risk.
• Calm safety steps, not argument, address paranoia and psychosis-like states.